Tumor biotherapy is an emerging tumor treatment mode with remarkable efficacy, which is a new type of autoimmune anti-cancer treatment method. It is a new treatment method of autoimmunity against cancer. It uses biotechnology and biological agents to stimulate and enhance the body’s own immune function by culturing and amplifying immune cells collected from patients in vitro and then transfusing them back into the patient’s body, so as to achieve the purpose of treating tumors. Tumor biotherapy is the fourth major tumor treatment technology after surgery, radiotherapy and chemotherapy. (1) At the end of 19th century, Coley used Streptococcus pyogenes and Listeria monocytogenes filtrate to treat cancer, which was called Coley therapy. (2) In 1953, Feley and Preho discovered tumor-specific transplant antigens in animals and established the modern concept of tumor immunity, followed by the clinical application and animal experiments of various non-specific biological agents (BCG, Corynebacterium shortum, immune ribonucleic acid, transfer factor, etc.), which laid the scientific foundation for human tumor immunotherapy. (3) In the mid-1980s, Bosenberg and oldham proposed the concept of biological response modulation (BRM), which established the theoretical and technical basis of modern tumor biotherapy. (4) From the late 1980s to the present: the application of cytokines, tumor vaccines, monoclonal antibodies, stem cells, immune lymphocytes and gene therapy methods have obtained promising results. Tumor biotherapy is the fourth major treatment method after surgery, radiotherapy and chemotherapy. Since the development of traditional surgery and radiotherapy has entered a plateau, people have put more and more attention on the biological treatment of tumors. In recent years, biological therapy for tumors has been developed significantly, and its important role in improving patients’ survival quality and reducing recurrence rate has been increasingly recognized and valued. DC-CIK cellular immunotherapy technology is the fourth form of cancer treatment recognized worldwide after surgery, radiotherapy and chemotherapy, and is also known as the treatment that is expected to completely overcome cancer in the 21st century. It is also known as the “green biological therapy” for oncology because of its high safety and non-toxic side effects. DC-CIK cellular immunotherapy is one of the most widely used and mature tumor biotherapy techniques. The immune system is the defense system of human body. On one hand, it plays the function of removing bacteria, viruses and foreign substances, on the other hand, it eliminates the aging cells and mutated cells in the body (some mutated cells will become cancer cells). The result of the interaction between the immune system and cancer cells determines the final evolution of cancer. In a healthy person, the immune system is strong enough to remove the mutated cancer cells in time. However, for cancer patients, the immune system is generally low and cannot effectively identify and kill cancer cells; on the other hand, the proliferation of cancer cells will further suppress the immune function of patients, and, cancer cells have multiple mechanisms to escape from the recognition and killing of immune cells, immunotherapy of cancer is to improve the immunogenicity of cancer with the help of molecular biology technology and cell engineering technology, and to give the body Immunotherapy for cancer is to enhance the immunogenicity of cancer, replenish the body with sufficient number of normal functioning immune cells and related molecules, stimulate and enhance the body’s anti-tumor immune response, increase the sensitivity of cancer to the body’s anti-cancer immune effect, induce cancer-specific and non-specific taste effector cells and molecules in vivo and externally, and achieve the ultimate purpose of cancer clearance. Cancer biotherapy, its effect is not to kill all cancer cells, but to treat cancer by removing tiny residual lesions or significantly inhibiting the proliferation of residual cancer cells due to the recovery of the body’s immune function when the cancer cell load is significantly reduced. Cancer immunotherapy is precisely to mobilize the body’s own immune system to kill and inhibit the proliferation of cancer cells through human intervention. After the primary cancer is surgically removed or the local cancer is ablated by minimally invasive surgery such as argon fluoride knife, immunotherapy can kill the remaining cancer cells, eliminate the factors of recurrence and metastasis, increase the possibility of cure, prolong the survival time and improve the quality of life. Currently, cancer biotherapy has been regarded as the fourth treatment method after surgery, radiotherapy and chemotherapy. Biological therapies include cytokine therapy, immune cell therapy, gene therapy, molecular targeted therapy and antibody therapy, etc. V. Classification of tumor biological therapy Biological therapy is divided into cell therapy and non-cell therapy. Tumor cell therapy Cell therapy often requires the collection of the patient’s own cells for preparation and then transfusion back to the patient, so it cannot be produced on a large scale, and this treatment method is more suitable to be carried out in medical institutions to complete the whole process from collection, preparation to transfusion. According to the order of application and research, tumor cell therapy is divided into: (1) lymphokine-activated killer cells (LAK); (2) tumor infiltrating lymphocyte (TIL); (3) cytokine-induced killer cells (CIK); (4) dendritic cells (CIK); and (5) tumor-infiltrating lymphocytes (TIL). (4) dendritic cells (DC); (5) natural killer cells (NK). 2, non-cellular therapy include: (1) antibody therapy by lymphocyte hybridoma monoclonal antibody technology or genetic engineering technology to prepare monoclonal antibody (monoclonal antibody) drugs is a technology in biological therapy. It has the characteristics of pure nature, high potency, high specificity, little or no serum cross-reactivity, etc., and plays an important role in the treatment of tumors. (2) Peptide vaccine Tumor peptide vaccine has become a new method of tumor immunotherapy because of the advantages of simple production process, low cost, chemical stability and non-carcinogenicity. (3) Targeted drug therapy Gene-targeted therapy for tumors is a new medical field that integrates multiple disciplines and technologies, and many new technical methods have emerged in recent years. Targeted drugs often have certain side effects such as rash, diarrhea, vomiting and liver function disorders while treatment. Due to the high price and the need to take them continuously, they cause a burden to many patients and families. (4) Cytokine therapy Cytokines are a collective name for small molecule peptides secreted by various cells that can regulate cell growth and differentiation, regulate immune function, and participate in inflammation and wound healing. Immunoglobulins and complement are not included in cytokines. (5) DC+CIK cell immunotherapy DC+CIK cell immunotherapy is to culture stem cells in vitro, induce their differentiation into dendritic cells, and then induce CIK cells with antigen-stimulated dendritic cells to produce specific tumor-killing effects. DCs are the most powerful antigen-presenting cells discovered to date (i.e., they provide tumor-related information to cells with tumor-killing activity that normally exist in the human body) and play a role similar to a “radar” in the human immune system; CIK is a class of peripheral blood single nuclei cells that are induced in vitro by a combination of cytokines. CIK is a heterogeneous population of CD3+ CD56+ T cells, which are the main effector cells of peripheral blood mononuclear cells, produced in vitro after induction by a variety of cytokines, so CIK has the effect of both T cells and NK cells, which are the main anti-tumor active cells in human body. Medical doctors describe it more graphically: if T cells in the human immune system as a “shell” role, then CIK is equivalent to a more powerful “missile”. Six, CIK cells kill tumor cells mainly through the following four ways: (a), CIK cells can identify tumor cells by different mechanisms, through direct cytoplasmic particles to penetrate the closed tumor cell membrane, to achieve the lysis of tumor cells; (b), through the induction of apoptosis to kill tumor cells; (c), CIK cells secrete IL-2, IL-6, IFN-γ and many other (d), CIK cells can activate the body’s immune system and improve the body’s immune function after transfusion. The combined application of DC+CIK cell therapy will achieve the efficacy of “1+1>2”, which can significantly inhibit the growth and proliferation of tumor cells, significantly improve the patient’s quality of life, and increase the survival of tumor patients, which is a new and more effective means after tumor surgery, radiotherapy and chemotherapy. This therapy can be used alone or as a powerful adjuvant after surgery, chemotherapy and radiotherapy with remarkable effect. Combined with surgical resection, intervention, radiofrequency, argon helium knife and other treatments, it can remove the very small tumor foci that cannot be removed by surgery or the tumor cells scattered in the body, and has an important role in delaying or stopping the metastasis or recurrence of tumor; for some tumor patients who are temporarily not suitable for surgery, intervention or other treatments, they can also undergo DC+CIK cell therapy first, so as to improve their physical function, improve their quality of life and strive for other treatment opportunities. For some tumor patients who are temporarily suitable for surgery, interventional or other treatments, DC+CIK cell therapy can also be performed first to improve their physical function, improve their quality of life and seek other treatment opportunities. Because biological immunotherapy technology uses human body’s own immune cells instead of traditional chemicals to kill tumor cells, it is safe and non-toxic, and is applicable to all stages of cancer treatment, and has relieved countless cancer patients of their pain and brought them health benefits since its implementation. Tumor biotherapy is the latest tumor treatment technology that is superior to surgery, radiotherapy and chemotherapy. It is a treatment method to cultivate auto-immune cells that can kill tumor through biotechnology in a high-standard laboratory, and transfuse them back into the body to kill cancer cells directly. Unlike traditional treatment methods, tumor biotherapy directly identifies and destroys cancer cells existing in the blood and lymph of human body without damaging the immune system and functions of the body, and restores and enhances the natural anti-cancer immune system and functions of the body. Biological tumor therapy has the advantages of being non-invasive, painless, without hospitalization, etc. It can improve patients’ own immunity and quality of life, and is applicable to all tumor diseases, and this biological therapy technology has been officially applied in clinical practice. Biological cell immunotherapy is the fourth major tumor treatment technology after surgery, radiotherapy and chemotherapy. Biological cell immunotherapy has the following advantages in treating tumors: 1. For some cancers, the efficiency is as high as 70%. 2. No toxic side effects of radiotherapy and chemotherapy, no pain for patients, good tolerance and strong specificity of tumor killing. 3. It can stimulate the systemic anti-cancer effect and is equally effective for multiple foci or metastatic malignant tumors. 4. It can help the body to quickly restore the anti-cancer immune system destroyed by radiotherapy and chemotherapy and improve the long-term anti-cancer ability. 5.It is effective in preventing recurrence of cancer after surgery and has good long-term anti-cancer effect. It can be used alone or in combination with other treatment methods. It is effective for single use and better for multiple use. It can prevent tumor recurrence and metastasis; patients with middle and late stage tumor who cannot undergo surgery, radiotherapy and chemotherapy; patients with tumor who failed in radiotherapy and chemotherapy; patients with tumor who undergo comprehensive treatment after radiotherapy and chemotherapy, which can reduce the side effects of radiotherapy and chemotherapy; patients with leukemia after bone marrow transplantation or chemotherapy remission; patients with cancerous thoracic and abdominal effusion; patients who are temporarily unsuitable for surgery, intervention or other treatments. Patients who are not suitable for surgery, intervention or other treatments. In the face of the rapid and diversified development of tumor treatment technology, more and more patients choose to apply immune cell therapy technology, what kind of people are most suitable for immune cell therapy? One third of early stage tumors can be cured by immune cell therapy, so is immune cell therapy only applicable to early stage tumor patients? Can older patients undergo immune cell therapy? Can patients who are inoperable or failed in radiotherapy have immune cell therapy? In fact, immune cell therapy is not only applicable to the treatment of early stage tumor patients, but a few advanced tumor patients can also achieve partial or complete remission after immune cell therapy. And because this treatment has no toxic side effects, it is also the best choice for those patients who are older, have poor body immunity and are afraid of toxic side effects of radiotherapy. At the same time, for those who are not sensitive to radiotherapy or cannot tolerate radiotherapy, and for some advanced tumor patients who are not suitable for surgery, interventional therapy and other treatments, cellular immunotherapy can improve the immune function of patients, improve the quality of life and prolong the survival period with tumor; some patients can significantly reduce the volume of tumor through immune cell therapy and strive for surgery or other treatment opportunities. XI. Indication groups of “targeted immunotherapy” tumor biotherapy in Biological Treatment Center 1. (lung cancer, stomach cancer, esophageal cancer, bile duct cancer, gallbladder cancer, pancreatic cancer, colon cancer, rectal cancer, colorectal cancer, breast cancer, ovarian cancer, cervical cancer, prostate cancer, bladder cancer, urethral cancer, etc.) and patients with chronic hematologic malignant diseases; 2. After the primary focus is removed (surgery, radiotherapy), targeted immunotherapy can be applied to prevent recurrence and metastasis; 3. For those with extensive tumor metastasis and unable to undergo surgery, it can be used with In the interval of chemotherapy, targeted immunotherapy can restore the damaged immune function of the body as soon as possible, and the combined application with some chemotherapy drugs can increase the effect of chemotherapy and immunotherapy at the same time. Some immune cells such as NK cells and T cells still have the effect of killing tumor cells with drug resistance genes. 4.Targeted immunotherapy can improve the immune function of patients, improve the quality of life and prolong the survival period with tumor; some patients can significantly reduce the volume of tumor through high-dose comprehensive targeted immunotherapy, and strive for surgery or other treatment opportunities. A few advanced tumor patients can also achieve partial or complete remission through targeted immunotherapy. 5.After conventional treatment (surgery and radiotherapy), patients who need to improve their own immune function. A small number of tumor patients who are not treated by radiotherapy and chemotherapy can also achieve significant effect through comprehensive targeted immunotherapy. The best period for biological tumor treatment is early stage tumor patients. In addition to surgery, radiotherapy and other therapeutic means, it is easier to implement cell biology technology and make full use of DC (dendritic cells) and CIK (cytokine-induced killer cells) to carry out autologous cancer cell killing therapy to effectively control the development of cancer cells until all tumor cells are killed. For most patients with early-stage tumors, it is even possible to work and treat at the same time. Secondly, patients with combined radiotherapy and chemotherapy Biological therapy technology can enhance the sensitivity of radiotherapy and reduce toxic side effects; resist the immunosuppressive effect of chemotherapy drugs, enhance the sensitivity to chemotherapy drugs and improve the efficacy of chemotherapy; rapidly relieve patients’ clinical symptoms, and most patients can achieve the effect of tumor shrinkage or even disappearance, or long-term survival with tumor. For patients who are ineffective in radiotherapy, biological therapy can also be used to prolong survival. Thirdly, patients who cannot tolerate surgery and radiotherapy The cells have a strong ability to recognize tumor cells, so for those patients who are relatively weak, miss the best treatment period of surgery and cannot tolerate the response of radiotherapy, it is more suitable to use biological treatment technology. Fourthly, patients recovering from surgery Because tumor biotechnology has immunomodulatory and autologous cell repair effects, while treating tumors, most patients, especially those after radiotherapy, will show “rejuvenation” such as reduction or disappearance of digestive symptoms, luster of skin, fading of dark spots, disappearance of varicose veins, stopping hair loss and restoring growth, turning gray hair into black hair, etc. “They will also have obvious recovery of mental state and physical strength. Fifth, advanced tumor patients For patients with advanced tumor, metastasis and weak constitution, all of them can choose the most advanced biological treatment technology, which first activates the immune function in the body, recognizes and kills tumor through immune cells with high specific function, promotes the treatment, controls the metastasis and recurrence of tumor, and brings new hope for those patients who are desperate and lose confidence in treatment – -It can effectively prolong the survival time of patients and improve the quality of survival! Contraindications 1.Pregnant women or breastfeeding women; 2.Patients with T-cell lymphoma; 3.Patients with uncontrollable serious infection; 4.Patients who are allergic to IL-2 and other biological products; 5.Patients with AIDS; 6.Patients who are undergoing systemic radiotherapy or chemotherapy; 7.Patients with advanced tumor causing cachexia or low peripheral blood count; 8.Patients with organ failure; 9.Organ transplantation; 10 10.Patients who use or are using immunosuppressants for a long time. XIV. Domestic and foreign status China Several tumor gene therapy programs such as TK gene therapy for malignant glioma, dendritic cell-based tumor somatic cell gene therapy, interleukin 22 gene therapy for gastric cancer, hsv2tk gene therapy for liver cancer, etc. have entered the clinical trial stage, and recombinant adenovirus 2p53 anti-cancer injection (SBN21), as the first gene therapy drug in the world, was approved by SFDA in October 2003. In October 2003, it was approved by SFDA and entered the trial production stage. Foreign 918 clinical trial protocols in the United States, 589 in Phase I, 185 in Phase I/II, 120 in Phase II, 9 in Phase II/III, and 15 in Phase III. (1) Histocompatibility antigens, such as HLA2B7 for rectal cancer; (2) Tumor suppressor genes, such as Adp53 for neck tumors and non-small cell lung cancer, and BRCA1 for ovarian cancer; (3) Cytokines, such as IL-2 for metastatic breast cancer, and IL-7 and IL-12 modified tumor vaccines for enhanced anti-tumor effects.